Patient leaflet - Suvaxyn PRRS MLV
B. PACKAGE LEAFLET
PACKAGE LEAFLET:
Suvaxyn PRRS MLV lyophilisate and solvent for suspension for injection for pigs
-
1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT
Marketing authorization holder and manufacturer responsible for batch release:
Zoetis Belgium SA
Rue Laid Burniat 1
1348 Louvain-la-Neuve
BELGIUM
-
2. NAME OF THE VETERINARY MEDICINAL PRODUCT
Suvaxyn PRRS MLV lyophilisate and solvent for suspension for injection for pigs
-
3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
Each dose (2 ml) contains:
Lyophilisate:
Active substance:
Modified live PRRSV*, strain 96V198: 102.2 – 105.2 CCID50**
-
* Porcine respiratory and reproductive syndrome virus
-
* * Cell culture infectious dose 50%
Solvent:
Sodium chloride 0.9% solution: qs 1 dose.
Lyophilisate: off-white freeze-dried pellet.
Solvent: clear, colourless solution.
-
4. INDICATION(S)
For active immunisation of clinically healthy pigs from 1 day of age in a porcine respiratory and reproductive syndrome (PRRS) virus contaminated environment, to reduce viraemia and nasal shedding caused by infection with European strains of PRRS virus (genotype 1).
Onset of immunity: 21 days after vaccination.
Duration of immunity: 26 weeks after vaccination.
Fattening pigs:
In addition, vaccination of seronegative 1 day-old piglets was demonstrated to significantly reduce lung lesions against challenge administered at 26 weeks post vaccination. Vaccination of seronegative 2 weeks-old piglets was demonstrated to significantly reduce lung lesions and oral shedding against challenge administered at 28 days and at 16 weeks post vaccination.
Gilts and sows:
In addition, pre-pregnancy vaccination of clinically healthy gilts and sows, non-PRRS virus-naïve (i.e. either previously immunised against PRRS virus via vaccination or exposed to PRRS virus via field infection) or PRRS virus-naïve, was demonstrated to reduce the transplacental infection caused by PRRS virus during the last third of pregnancy, and to reduce the associated negative impact on reproductive performance (reduction of the occurrence of stillbirths, of piglet viraemia at birth and at weaning, of lung lesions and of viral load in lungs in piglets at weaning).
-
5. CONTRAINDICATIONS
Do not use in herds where European PRRS virus has not been detected by reliable diagnostic methods.
Do not use in boars producing semen, as PRRS virus can be shed in semen.
Do not use in PRRS virus-naïve pregnant gilts and sows in the second half of gestation because the vaccine strain may cross the placenta. The administration of the vaccine to pregnant PRRS virus-naïve gilts and sows in the second half of gestation may have an impact on their reproductive performance.
-
6. ADVERSE REACTIONS
A transient increase in rectal temperature (0.5 °C on average, and up to 1.4 °C individually) may very commonly occur within 4 days after vaccination. Local reactions in the form of swellings are common and resolve spontaneously within 3 days. The area of local tissue reaction is in general below 2 cm in diameter. Anaphylactic-type reactions (vomiting, tremors and/or mild depression) may uncommonly occur in piglets shortly after vaccination. These resolve without treatment within few hours.
A minor and transient increase in rectal temperature (0.2 °C on average, and up to 1.0 °C individually) may very commonly occur 4 hours post vaccination in pre-breeding PRRS virus-naïve gilts and sows. Local reactions in the form of swellings are very common and resolve spontaneously within 5 days. The area of local tissue reaction is in general below 0.5 cm in diameter.
A minor and transient increase in rectal temperature (0.8 °C on average, and up to 1.0 °C individually) may very commonly occur 4 hours post vaccination in PRRS virus-naïve gilts and sows in the first half of pregnancy. Local reactions in the form of swellings are very common and resolve spontaneously within 9 days. The area of local tissue reaction is in general below 1.4 cm in diameter.
A minor and transient increase in rectal temperature (0.4 °C on average, and up to 0.6 °C individually) may very commonly occur 4 hours post vaccination in non-PRRS virus-naïve gilts and sows in the second half of pregnancy. Local reactions in the form of swellings are very common and resolve spontaneously within 32 days. The area of local tissue reaction is in general below 5 cm in diameter.
The frequency of possible adverse effects is defined using the following convention:
-
– very common (more than 1 in 10 animals treated displaying adverse reaction(s))
-
– common (more than 1 but less than 10 animals in 100 animals treated)
-
– uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
-
– rare (more than 1 but less than 10 animals in 10,000 animals treated)
-
– very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.
-
7. TARGET SPECIES
Pigs (pigs for fattening, gilts and sows).
-
8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION
Intramuscular injection: 2 ml in the neck.
Pigs for fattening: A single dose of 2 ml is given to pigs from 1 day of age onwards.
Gilts and sows: A single dose of 2 ml is given prior to introduction into the sow herd, approximately 4 weeks prior to breeding. A single booster dose is given every 6 months.
-
9. ADVICE ON CORRECT ADMINISTRATION
Reconstitute the lyophilisate with the supplied solvent. In cases where the vials containing the solvent and the lyophilisate are stored separately, verify prior to reconstituting the lyophilisate that the lot number mentioned on the vial containing the solvent is identical to the lot number mentioned on the vial containing the lyophilisate. Transfer approximately 5 ml of solvent to the vial containing the lyophilisate and ensure complete reconstitution. Transfer back the reconstituted solution into the solvent vial (containing the remaining solvent): 25 doses are reconstituted into 50 ml solvent, 50 doses are reconstituted into 100 ml solvent, and 125 doses are reconstituted into 250 ml solvent.
Mass vaccination can be used in herds in which the prevalence of European PRRS virus has been established.
Use sterile syringes and needles.
The use of a multi-dosing syringe is recommended. Use vaccination devices according to the manufacturer’s instructions.
Needles for administration should be appropriate for the size of the pig.
10.
WITHDRAWAL PERIOD(S)
Zero days.
11. SPECIAL STORAGE PRECAUTIONS
Keep out of the sight and reach of children. Store and transport refrigerated (2 °C – 8 °C).
The solvent may be stored outside a refrigerator at 15 °C – 25 °C.
Do not freeze.
Protect from light.
Do not use this veterinary medicinal product after the expiry date which is stated on the carton and the vial after EXP.
Shelf life after reconstitution: use immediately.
12.
SPECIAL WARNING(S)
Special warnings for each target species:
Vaccinate healthy animals only.
Special warnings for use in animals:
Care should be taken to avoid the introduction of the vaccine strain into an area where PRRS virus is not already present.
Vaccinated animals may excrete the vaccine strain for more than 16 weeks following vaccination. The vaccine strain can spread to in contact pigs. The most common spreading route is via direct contact, but spreading via contaminated objects or via the air cannot be excluded.
Special precautions should be taken to avoid spreading of the vaccine strain to unvaccinated animals (e.g. PRRS virus-naïve pregnant gilts and sows in second half of gestation) that should remain free from PRRS virus.
Newly introduced PRRS virus-naïve females (e.g. replacement gilts from PRRS virus-negative herds) should be vaccinated prior to introduction into the herd of non-PRRS virus-naïve animals and prior to pregnancy.
It is advised to vaccinate all target pigs within a herd from the earliest recommended age onwards.
In order to limit the potential risk of recombination between PRRS vaccine strains do not use different PRRS MLV vaccines on the same farm at the same time. Do not routinely rotate two or more commercial PRRS MLV vaccines in a herd with the intention to improve cross-protection.
Pregnancy :
Can be used in PRRS virus-naïve gilts and sows pre-breeding or in the first half of gestation.
Can be used in non-PRRS virus-naive gilts and sows in the second half of gestation.
Lactation :
The safety of the vaccine has not been established during lactation.
Interaction with other medicinal products and other forms of interaction:
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
Overdose (symptoms, emergency procedures, antidotes):
Upon administration of a 10-fold overdose in piglets, anaphylactic-type reactions (tremor, apathy and/or vomiting) were very commonly observed shortly after vaccination; these signs resolved without treatment within a few hours. A transient increase in rectal temperature (0.3 °C on average, and up to 1.2 °C individually) very commonly occurred 24 hours post vaccination. Local reactions, in the form of soft/hard swelling (below or equal to 0.7 cm diameter) without heat or pain, were very commonly observed at the injection site and resolved within 5 days.
The administration of a 10-fold overdose to PRRS virus-naïve pre-breeding or pregnant gilts and sows in the first or second half of pregnancy induced similar adverse reactions as those described under section 6. The maximum size of the local reactions was bigger (2 cm) and the maximum duration was in general longer (up to 9 days in pre-breeding sows).
After the administration of a 10-fold overdose to non-PRRS virus-naive gilts and sows in the second half of pregnancy a transient increase in rectal temperature (0.3 °C on average, and up to 0.6 °C individually) occurred 4 hours post vaccination. A local reaction involving transiently the whole neck region was very commonly observed (red-purple dark, erythematous swelling, causing itching, vesicle formation, increased local temperature, and, occasionally, pain). The reaction evolved to form hard tissue and formation of a scab, which very commonly lasted up to more than 44 days.
Incompatibilities :
Do not mix with any other veterinary medicinal product.
-
13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE
MATERIALS, IF ANY
Medicines should not be disposed of via wastewater or household waste. Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.
-
14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED